These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21119083)

  • 1. Transplacental antibody transfer following maternal immunization with a pandemic 2009 influenza A(H1N1) MF59-adjuvanted vaccine.
    Zuccotti G; Pogliani L; Pariani E; Amendola A; Zanetti A
    JAMA; 2010 Dec; 304(21):2360-1. PubMed ID: 21119083
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seroprevalence of influenza A H1N1 and seroconversion of mothers and infants induced by a single dose of monovalent vaccine.
    Chao A; Huang YC; Chang YL; Wang TH; Chang SD; Wu TS; Wu TL; Chao AS
    Taiwan J Obstet Gynecol; 2013 Sep; 52(3):356-9. PubMed ID: 24075373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals.
    Kajaste-Rudnitski A; Galli L; Nozza S; Tambussi G; Di Pietro A; Pellicciotta G; Monti A; Mascagni P; Moro M; Vicenzi E
    AIDS; 2011 Jan; 25(2):177-83. PubMed ID: 21150561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-centre observational study of transplacental transmission of influenza antibodies following vaccination with AS03(A)-adjuvanted H1N1 2009 vaccine.
    Puleston R; Bugg G; Hoschler K; Konje J; Thornton J; Stephenson I; Myles P; Enstone J; Augustine G; Davis Y; Zambon M; Nicholson K; Nguyen-Van-Tam J
    PLoS One; 2013; 8(1):e47448. PubMed ID: 23372640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
    Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
    Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of timing of maternal influenza immunization on infant antibody levels at birth.
    Zhong Z; Haltalli M; Holder B; Rice T; Donaldson B; O'Driscoll M; Le-Doare K; Kampmann B; Tregoning JS
    Clin Exp Immunol; 2019 Feb; 195(2):139-152. PubMed ID: 30422307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influenza vaccination given at least 2 weeks before delivery to pregnant women facilitates transmission of seroprotective influenza-specific antibodies to the newborn.
    Blanchard-Rohner G; Meier S; Bel M; Combescure C; Othenin-Girard V; Swali RA; Martinez de Tejada B; Siegrist CA
    Pediatr Infect Dis J; 2013 Dec; 32(12):1374-80. PubMed ID: 24569309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus.
    Zuccotti GV; Pariani E; Scaramuzza A; Santoro L; Giani E; Macedoni M; Gazzarri A; Anselmi G; Amendola A; Zanetti A
    Diabet Med; 2011 Dec; 28(12):1530-6. PubMed ID: 21916971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months.
    Esposito S; Pugni L; Daleno C; Ronchi A; Valzano A; Serra D; Mosca F; Principi N
    Pediatrics; 2011 May; 127(5):e1161-8. PubMed ID: 21464195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers.
    Hsu JP; Phoon MC; Koh GC; Chen MI; Lee VJ; Wu Y; Xie ML; Cheong A; Leo YS; Chow VT
    Int J Infect Dis; 2012 Aug; 16(8):e621-7. PubMed ID: 22704721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children.
    Meier S; Bel M; L'huillier A; Crisinel PA; Combescure C; Kaiser L; Grillet S; Pósfay-Barbe K; Siegrist CA;
    Vaccine; 2011 Apr; 29(19):3548-57. PubMed ID: 21419775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children.
    Block SL; Ruiz-Palacios GM; Guerrero ML; Beygo J; Sales V; Holmes SJ
    Pediatr Infect Dis J; 2012 Jul; 31(7):e92-8. PubMed ID: 22481427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients.
    Fairhead T; Hendren E; Tinckam K; Rose C; Sherlock CH; Shi L; Crowcroft NS; Gubbay JB; Landsberg D; Knoll G; Gill J; Kumar D
    Transpl Infect Dis; 2012 Dec; 14(6):575-83. PubMed ID: 22999005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Serodiagnosis in the surveillance of the influenza virus circulation during the development of the pandemic caused by the A (H1N1)pdm09].
    Mukasheva E; Kolobukhina LV; Merkulova LV; Kisteneva LB; Zaplatnikov AL; Smolonogina TA; Desheva YA; Mikhaylova EV; Romanovskaya AV; Dubovitskaya NA; Burtseva EI
    Vopr Virusol; 2015; 60(6):19-24. PubMed ID: 27024912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Learning from the 2009 H1N1 pandemic: prospects for more broadly effective influenza vaccines.
    Settembre EC; Dormitzer PR; Rappuoli R
    J Mol Cell Biol; 2011 Jun; 3(3):144-6. PubMed ID: 21430014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children.
    Örtqvist Å; Bennet R; Hamrin J; Rinder MR; Lindblad H; Öhd JN; Eriksson M
    Vaccine; 2015 May; 33(22):2558-61. PubMed ID: 25869891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody response to the non-adjuvanted and adjuvanted influenza A H1N1/09 monovalent vaccines in renal transplant recipients.
    Salles MJ; Sens YA; Malafronte P; Souza JF; Vilas Boas LS; Machado CM
    Transpl Infect Dis; 2012 Dec; 14(6):564-74. PubMed ID: 22882692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Observational study to investigate vertically acquired passive immunity in babies of mothers vaccinated against H1N1v during pregnancy.
    Puleston RL; Bugg G; Hoschler K; Konje J; Thornton J; Stephenson I; Myles P; Enstone J; Augustine G; Davis Y; Zambon M; Nicholson KG; Nguyen-Van-Tam JS
    Health Technol Assess; 2010 Dec; 14(55):1-82. PubMed ID: 21208547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.